secwatch.observer — SEC 8-K summary
======================================

Issuer:     United Health Products, Inc. (UEEC)
CIK:        0001096938
Form:       8-K
Filed at:   2026-07-10T16:19:24+00:00
Accession:  0001477932-26-004244
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Health Products partners with NAMSA to sponsor clinical study of CelluSTAT for FDA PMA
--------------------------------------------------------------------------------

- NAMSA will serve as regulatory sponsor, seeking an IDE to conduct a clinical study of CelluSTAT Hemostatic Gauze.
- UHP will hold exclusive right of reference to all study data for use in a revised PMA application.
- The study is part of efforts to resolve the outstanding FDA Warning Letter.
- NAMSA has decades of experience in clinical trial management for Class III hemostatic agents and FDA CDRH.
- CEO Brian Thom expressed confidence in NAMSA's ability to gain IDE approval and efficiently sponsor the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1096938/000147793226004244/0001477932-26-004244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1096938/000147793226004244/ueec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-004244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer